Source disclosure: February 16, 2026
TAKARA BIO INC. [4974.T]
TOKYO — Takara Bio Inc., represented by President and CEO Tsuyoshi Miyamura, has issued an announcement regarding corrections to its board's recommendation supporting a tender offer from parent company Tomy Holdings Co. Ltd. The corrections were made following a review of the supplementary documents attached to the statement released on February 12, 2026.
The special committee of Takara Bio submitted a report to the company’s board on February 12, which included recommendations endorsing the public tender offer initiated by Tomy Holdings for Takara Bio shares. However, it was discovered that there were minor errors in one of the appended documents, necessitating this correction notice. Specifically, the issue pertained to a missing portion of text within the document detailing the first meeting agenda of the special committee.
According to the corrected version, the first meeting held on November 12, 2026, covered several key topics including an overview of the proposed transaction, the establishment purpose of the special committee, advisory matters, and the authority granted to the committee members. Additionally, the meeting addressed measures taken by Oe Hashibashi Law Office to ensure fairness, confirmed the independence of committee members, elected the chairperson and deputy chairperson, reviewed the independence of external advisors (FA/LA), and discussed the anticipated timeline for the process.
This update ensures transparency and accuracy in the information provided to shareholders, reinforcing the board's commitment to thorough due diligence and clear communication during significant corporate transactions. Shareholders are encouraged to refer to the revised materials for a comprehensive understanding of the tender offer process and timelines.
AI-translated content. 🟢 Confidence: High See terms • Original filing